TREATMENT OF NON-SECRETING PITUITARY ADENOMAS WITH CHIMERIC MOLECULES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目从7月7日开始在MR 7T日历上进行，预订时间为每周一至9月22日(共12次扫描)，每只动物每月一次，持续4-5个月；小鼠在6-8个月大时患上脑垂体瘤。 目的1：比较生长抑素和多巴胺嵌合分子(生长抑素和多巴胺嵌合体)与单纯生长抑素和多巴胺药物在阻止垂体腺瘤生长方面的有效性。 目的2：确定携带垂体腺瘤并接受嵌合分子治疗的小鼠与单纯赋形剂(后者将在10-11个月龄前死亡)的存活率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project has been scheduled on the MR 7T calendar starting on July 7, with reservations for every Monday through Sept 22 ( a total of 12 scanning sessions), once/month per animal for 4-5 months; mice develop pituitary tumors by 6-8 months of age. Aim 1: Compare the proven effectiveness in halting pituitary adenoma growth of a chimeric molecule (chimera of somatostatin and dopomine) to that of a pure somatostatin and dopamine drug. Aim 2: Determine the survival of mice carrying pituitary adenomas and being treated with the chimeric molecule versus just vehicle (the latter group will die by 10-11 months of age).